Literature DB >> 2532421

Follow-up study of atlanto-axial instability in Down's syndrome without separate odontoid process.

T Ohsawa1, T Izawa, Y Kuroki, K Ohnari.   

Abstract

Clinical and roentgenologic studies were performed in 69 children with Down's syndrome, without the separate odontoid process, that could be followed for more than 5 years. At the follow-up examination, the atlanto-odontoid process interval (AOI) in flexion, neutral, and extension of the cervical vertebrae significantly decreased when compared with the one at the initial examination. This was particularly obvious up to 5 years of age. Although 14 of 69 cases (20.3%) had atlanto-axial instability at the initial examination, this decreased to four cases (5.8%) at the follow-up examination. However, there were two cases of atlanto-axial instability who were over 10 years of age. There was no significant difference in the minimum sagittal diameter (MSD) at the atlantal level between each position at both the initial and follow-up examinations. Moreover, there was a tendency for the MSD of the cases of positive instability at the follow-up examination to be smaller than those of the cases of negative instability. The degree of ligament laxity improved with increasing age and there was statistically the negative correlation. Although there was a tendency for the AOI to decrease with improvement of the degree of ligament laxity, the correlation could not be confirmed.

Entities:  

Mesh:

Year:  1989        PMID: 2532421     DOI: 10.1097/00007632-198911000-00004

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  2 in total

Review 1.  Imaging the craniocervical junction.

Authors:  Wendy R K Smoker; Geetika Khanna
Journal:  Childs Nerv Syst       Date:  2008-05-07       Impact factor: 1.475

2.  Atlantoaxial instability in Down's syndrome: a five year follow up study.

Authors:  R E Morton; M A Khan; C Murray-Leslie; S Elliott
Journal:  Arch Dis Child       Date:  1995-02       Impact factor: 3.791

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.